Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) is projected to post its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.11) per share and revenue of $51.91 million for the quarter.
Vanda Pharmaceuticals Stock Up 2.0 %
VNDA stock traded up $0.09 during trading on Wednesday, reaching $4.53. The company's stock had a trading volume of 497,989 shares, compared to its average volume of 602,572. The company's fifty day moving average is $4.72 and its 200-day moving average is $4.98. The company has a market capitalization of $264.14 million, a P/E ratio of -16.18 and a beta of 0.77. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75.
Wall Street Analyst Weigh In
Several analysts recently issued reports on VNDA shares. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Tuesday. They issued a "hold" rating on the stock.
View Our Latest Stock Analysis on VNDA
Insider Buying and Selling
In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now owns 44,857 shares of the company's stock, valued at $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.90% of the stock is owned by company insiders.
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
